AntineoplasticsLack of efficacy, immune-related hyperthermia and immune-related pneumonitis: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2021年 / 1864卷 / 1期
关键词：
D O I：
10.1007/s40278-021-98973-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：43 / 43
相关论文
共 50 条
  • [21] Immune-Related Colitis Induced by Camrelizumab: A Case Report
    Cheng, Sheng
    Yang, Yun
    Yu, Junxian
    Chen, Wei
    Li, Xingang
    [J]. JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 1727 - 1731
  • [22] Could immune-related hepatitis rapidly progress to immune-related cirrhosis?
    Lei, Y. -n.
    LI, X. -y.
    Gao, G.
    Wang, W. -y.
    Liang, Z. -y.
    Wang, Y. -s.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (04) : 1436 - 1442
  • [23] Immune-related gastritis: An orphan immune-related adverse event.
    Etan, Tal
    Shachar, Shlomit Strulov
    Wolf, Ido
    Leshem, Yasmin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Cemiplimab/PembrolizumabImmune-mediated pneumonitis, immune-related colitis and lack of efficacy
    [J]. Reactions Weekly, 2024, 2001 (1) : 90 - 90
  • [25] Immune-related gigantomastia: a case study
    Lozito, Alessia
    Gemelli, Maria
    Micello, Donata
    Vinci, Valeriano
    Pelosi, Giuseppe
    Ricotta, Riccardo
    [J]. IMMUNOTHERAPY, 2023, 15 (13) : 1001 - 1007
  • [26] Camrelizumab/octreotide/sorafenibLack of efficacy and immune-related adverse events: case report
    [J]. Reactions Weekly, 2023, 1939 (1) : 124 - 124
  • [27] Immunosuppressants/pembrolizumabImmune-related hepatitis, immune-related retinopathy and lack of efficacy: case report
    [J]. Reactions Weekly, 2023, 1958 (1) : 281 - 281
  • [28] Gimeracil/oteracil/tegafur/nivolumabRashes all over the body and immune-related pneumonitis: case report
    [J]. Reactions Weekly, 2023, 1957 (1) : 273 - 273
  • [29] Identification of immune-related biomarkers in adrenocortical carcinoma Immune-related biomarkers for ACC
    Peng, Yun
    Song, Yuxuan
    Ding, Jin
    Li, Nan
    Zhang, Zheyu
    Wang, Haitao
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 88
  • [30] Nivolumab/pazopanibLack of efficacy and immune-related neutropenia
    [J]. Reactions Weekly, 2024, 2003 (1) : 655 - 655
12345